Many new medicines that work directly on the body’s immune system are being studied for the treatment of COPD. In 2024, Dupixent became the first of these medicines to be approved for COPD.

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

The FDA has cleared the start of clinical trial testing of KT-621, an experimental oral medication for COPD and other ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

Dupixent for the treatment of COPD has been approved in more than 30 countries worldwide, including the 27 countries in the EU. Professor Kang Jian Chair of COPD Branch, Chinese Association of ...

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval ...